NCT00531050 - Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Indacaterol

Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).

DRUG

Placebo

Single dose indacaterol matching placebo via Concept 1 device

DRUG

Salmeterol

Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.

Trial Locations (1)

Unknown

Novartis Investigative site, Antwerp